Dennis A. Ausiello

Age: 72

Director, Center for Assessment Technology and Continuous Health (CATCH). Physician-in-Chief, Emeritus at Massachusetts General Hospital and Chief of Medicine at Massachusetts General Hospital from 1996 until 2013. Jackson Distinguished Professor of Clinical Medicine at Harvard Medical School.

President of the Association of American Physicians in 2006. Member, National Academy of Medicine and a Fellow of the American Academy of Arts and Sciences. Director of Alnylam Pharmaceuticals, Inc., Seres Therapeutics, Inc. and TARIS BioMedical LLC.

Pfizer Director since 2006. Member of our Science and Technology Committee and Lead Independent Director.

Ronald E. Blaylock

Age: 58

Founder, Managing Partner of GenNx360 Capital Partners, a private equity firm focused on investing in industrial and business services companies in the U.S. middle market, since 2006. Prior to launching GenNx360 Capital Partners, Mr. Blaylock founded and managed Blaylock & Company, an investment banking firm. He has also held senior management positions at UBS, PaineWebber Group, and Citicorp.

Director of CarMax, Inc., Urban One, Inc., formerly Radio One, Inc. and W.R. Berkley, Inc., an insurance holding company. Director of Syncreon U.S., a for-profit private company. Member of the Board of Trustees of Carnegie Hall. Member of the Board of Overseers of New York University Stern School of Business. Member of the Board of Trustees of Prep for Prep, a not-for-profit organization.

Pfizer Director since 2017. Member of our Corporate Governance and Science and Technology Committees.

Albert Bourla, DVM, Ph.D.

Age: 56

Albert Bourla is the Chief Operating Officer (COO) of Pfizer, one of the world's premier innovative biopharmaceutical companies. As COO, Albert oversees the company's commercial, strategy, manufacturing and global product development functions. He is a member of the Company's Executive Leadership Team.

Prior to being named COO, Albert was the Group President of Pfizer Innovative Health, responsible for the Consumer Healthcare, Inflammation & Immunology, Internal Medicine, Oncology, Rare Disease and Vaccines business groups. He also created the Patient and Health Impact group, which was dedicated to developing solutions for increasing patient access, demonstrating the value of our innovations, and ensuring broader business model innovation.

Albert has almost 25 years of experience with Pfizer and has held a number of senior global positions across a range of markets and disciplines. Previously, Albert was the Group President of Pfizer's Global Vaccines, Oncology and Consumer Healthcare business, where he was instrumental in building a strong and competitive position in Oncology and expanded the company's leadership in Vaccines. Before that, he was President and General Manager of Pfizer's Established Products business, where he led the development and implementation of strategies and tactics related to Pfizer's off-patent portfolio (including legacy brands and generics).

Albert joined Pfizer's Animal Health Division in 1993 as Technical Director of Greece. He held positions of increasing responsibility across Europe before moving to Pfizer Global Headquarters in New York in 2001 to assume the role of U.S. Group Marketing Director for Animal Health. In 2004, he became Vice President of Business Development and New Products Marketing; supervising Pfizer Animal Health global licensing and acquisition activities, as well as the unit's R&D portfolio. In 2006, he was appointed Area President of Europe, Africa and Middle East and in 2009, he assumed additional responsibilities for Asia and Pacific.

Albert is a Doctor of Veterinary Medicine and holds a Ph.D. in the Biotechnology of Reproduction from the Veterinary School of Aristotle University. Albert is a member of the following boards: the Pfizer Foundation, which promotes access to quality health care and the Biotechnology Innovation Organization (Bio), the world's largest biotechnology trade association, where he serves on the Executive Committee.

Pfizer Director since 2018.

W. Don Cornwell

Age: 70

Chairman of the Board and Chief Executive Officer of Granite Broadcasting Corporation from 1988 until his retirement in August 2009, and served as Vice Chairman of the Board until December 2009.

Director of American International Group, Inc. and Avon Products, Inc. Director of the Edna McConnell Clark Foundation. Director of the Wallace Foundation from 2002 until 2012 and previously served as a Director of CVS Caremark (including two years as Chair of its Compensation Committee) for over 10 years. Trustee of Big Brothers Big Sisters of New York City.

Pfizer Director since 1997. Member of our Audit, Compensation, Regulatory and Compliance, and Science and Technology Committees.

Joseph J. Echevarria

Age: 61

Chief Executive Officer of Deloitte LLP (Deloitte), a global provider of professional services, from 2011 until his retirement in 2014. During his 36-year tenure with Deloitte, served in various leadership roles, including Deputy Managing Partner, Southeast Region Audit Managing Partner, and U.S. Managing Partner and Chief Operating Officer.

Director of The Bank of New York Mellon Corporation, Unum Group, a provider of financial protection benefits, and Xerox Corporation. Member of the President’s Export Council and former Member of the Presidential Commission on Election Administration. Chair Emeritus of My Brother’s Keeper Alliance. Member of the Board of Trustees of the University of Miami.

Pfizer Director since 2015. Member of our Audit, Corporate Governance, and Science and Technology Committees.

Frances D. Fergusson, Ph.D.

Age: 73

President Emeritus of Vassar College since 2006 and President from 1986 to 2006. Served on the Mayo Clinic Board for 14 years, the last four years as its Chairman, and as President of the Board of Overseers of Harvard University from 2007 through 2008.

Director of Wyeth from 2005 until 2009. Director of Mattel, Inc. A Trustee of The J. Paul Getty Trust (executive committee), Director of the Second Stage Theatre, Vice Chair of the Board of The John and Mable Ringling Museum of Art Foundation, Inc.

Pfizer Director since 2009. Chair of our Regulatory and Compliance Committee and member of our Corporate Governance and Science and Technology Committees.

Helen H. Hobbs, M.D.

Age: 65

Investigator of the Howard Hughes Medical Institute since 2002. Professor of Internal Medicine and Molecular Genetics, and Director of the McDermott Center for Human Growth and Development at the University of Texas Southwestern Medical Center.

Member of the American Society for Clinical Investigation and the Association of American Physicians. Elected to the National Academy of Medicine in 2004, the American Academy of Arts and Sciences in 2006, and the National Academy of Sciences in 2007. Received both the Clinical Research Prize (2005) and Distinguished Scientist Award (2007) from the American Heart Association. In 2012, received the inaugural International Society of Atherosclerosis Prize and, in 2015 received both the Pearl Meister Greengard Award and the Breakthrough Prize in Life Sciences. In 2016, received the Passano Award and the Gill Award.

Pfizer Director since 2011. Chair of our Science and Technology Committee and member of our Corporate Governance and Regulatory and Compliance Committees.

James M. Kilts

Age: 70

Founding Partner, Centerview Capital, a private equity firm, since 2006. Vice Chairman, The Procter & Gamble Company (Procter & Gamble), from 2005 to 2006. Chairman and Chief Executive Officer, The Gillette Company (Gillette), from 2001 to 2005 and President, Gillette, from 2003 to 2005. President and Chief Executive Officer, Nabisco Group Holdings Corporation (Nabisco), from 1998 until its acquisition in 2000.

Director of MetLife, Inc., The Simply Good Foods Company and Unifi, Inc. (a textile manufacturing company). Executive Chairman of the Board of Conyers Park Acquisition Corporation from 2016 until its merger with The Simply Good Foods Company in 2017. Non-Executive Director of the Board of Nielsen Holdings PLC (from 2016 until 2017), Chairman of the Board of Nielsen Holdings (from 2011 until 2013) and Chairman of the Nielsen Company B.V. (from 2009 to 2014). Chairman of Big Heart Pet Brands until 2015 and Director of Meadwestvaco Corporation until 2014. Life Trustee of Knox College and Trustee of the University of Chicago, a member of the Board of Overseers of Weill Cornell Medicine, and Founder and Co-Chair, Steering Committee, of the Kilts Center for Marketing at the University of Chicago Booth School of Business.

Pfizer Director since 2007. Member of our Compensation and Science and Technology Committees.

Dan R. Littman, M.D., Ph.D.

Age: 65

Helen L. and Martin S. Kimmel Professor of Molecular Immunology at the Skirball Institute of Biomolecular Medicine of NYU Langone Medical Center since 1995 and an Investigator of the Howard Hughes Medical Institute since 1987. Professor of Microbiology and Immunology at the University of California, San Francisco from 1985 to 1995.

Member of the National Academy of the Sciences and the Institute of Medicine. Fellow of the American Academy of Arts and Sciences and the American Academy of Microbiology. Founding Scientific Advisory Board Member of Vedanta Biosciences. Member of Scientific Advisory Boards at ChemoCentryx, Inc., the Cancer Research Institute and the Ragon Institute of MGH, MIT and Harvard. Founder and a scientific advisor to Orca Pharmaceuticals. Awarded the New York City Mayor’s Award for Excellence in Science and Technology (2004), the Ross Prize in Molecular Medicine (2013) and the Vilcek Prize in Biomedical Science (2016).

Pfizer Director since 2018. Member of our Corporate Governance and Science and Technology Committees.

Shantanu Narayen

Age: 54

President and Chief Executive Officer and Director (Chairman since 2017) of Adobe Systems Incorporated, a producer of creative and digital marketing software. Prior to his appointment as CEO in December 2007, held various leadership roles at Adobe, including President and Chief Operating Officer, Executive Vice President of Worldwide Products, and Senior Vice President of Worldwide Product Development.

Director of Dell Inc. from 2009 until October 2013 and Director of Metavante Technologies Inc. from 2007 until 2009. President of the Board of Adobe Foundation, which funds philanthropic initiatives around the world. Vice Chairman of the US-India Strategic Partnership Forum from January 2018 to present.

Pfizer Director since 2013. Member of our Compensation, Regulatory and Compliance, and Science and Technology Committees.

Suzanne Nora Johnson

Age: 60

Retired Vice Chairman, Goldman Sachs Group, Inc., since 2007. During her 21-year tenure with Goldman Sachs, served in various leadership roles, including Chair of the Global Markets Institute, Head of Global Research, and Head of Global Health Care.

Director of American International Group, Inc., Intuit Inc. and Visa Inc. Vice Chair, Board of Trustees of The Brookings Institution, Co-Chair of the Board of Trustees of the Carnegie Institution of Washington; Co-Chair of the Board of Trustees of the University of Southern California; and Member of the Global Agenda Council on the Future of Financial and Monetary Systems for the World Economic Forum.

Pfizer Director since 2007. Chair of our Audit Committee and member of our Regulatory and Compliance, and Science and Technology Committees.

Ian C. Read

Age: 64

Ian C. Read leads Pfizer, one of the world’s premier innovative biopharmaceutical companies, which brings therapies to patients that significantly improve their lives. These include medicines, vaccines and many of the world’s best-known consumer health care products.

Prior to being named Chairman of the Board in 2011 and Chief Executive Officer in December 2010, he served as Senior Vice President and Group President of the Worldwide Biopharmaceutical Businesses, which he led from 2006 through December 2010. In that role, he oversaw five global business units— Primary Care, Specialty Care, Oncology, Established Products and Emerging Markets. Mr. Read began his career with Pfizer in 1978 as an operational auditor. He worked in Latin America through 1995, holding positions including Chief Financial Officer, Pfizer Mexico, and Country Manager, Pfizer Brazil. In 1996, he was appointed President of Pfizer’s International Pharmaceuticals Group, with responsibility for Latin America and Canada. He became Executive Vice President, Europe, in 2000, was named a Corporate Vice President in 2001, and assumed responsibility for Canada, in addition to Europe, in 2002. Mr. Read later became accountable for operations in both the Africa/Middle East region and Latin America as well.

Ian is a Director of Kimberly-Clark Corporation. He also serves on the Boards of Pharmaceutical Research and Manufacturers of America  (PhRMA), International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) and the Partnership of New York City.

Ian received his B.Sc. in chemical engineering from London University Imperial College in 1974 and earned his Chartered Accountants certification from the Institute of Chartered Accountants of England and Wales.

Pfizer Director since 2010.

Stephen W. Sanger

Age: 71

Chairman of General Mills, Inc., a packaged food producer and distributor, from 1995 until his retirement in 2008 and its Chief Executive Officer from 1995 to 2007.

Former Chairman of the Grocery Manufacturers of America. Recipient of the Woodrow Wilson Award for Public Service in 2009. Chaired the Fiscal Policy Committee of the Business Roundtable and served as a director of Catalyst. Director of Wells Fargo & Company (Chairman since October 2016). Director of Target Corporation from 1996 until 2013.

Pfizer Director since 2009. Chair of our Corporate Governance Committee and member of our Audit and Science and Technology Committees.

James C. Smith

Age: 58

President and Chief Executive Officer and Director of Thomson Reuters Corporation, a provider of intelligent information for businesses and professionals, since January 2012 and its Chief Operating Officer from September 2011 to December 2011.   Chief Executive Officer, Thomson Reuters Professional Division, from 2008 to 2011. Prior to the acquisition of Reuters Group PLC by The Thomson Corporation (Thomson) in 2008, served as Chief Operating Officer of Thomson and as President and Chief Executive Officer of Thomson Learning's Academic and Reference Group.

Member of the International Business Council of the World Economic Forum, the International Advisory Boards of British American Business and the Atlantic Council.

Pfizer Director since 2014. Chair of our Compensation Committee and member of our Audit and Science and Technology Committees.